Back

Thrombin activatable fibrinolysis inhibitor promotes development of chronic thromboembolic pulmonary hypertension -A possible novel therapeutic target-

27 August 2017 (15:10 - 15:25)
Organised by:
Congress Presentation Part of: Young Investigator Awards Session Basic Science Chronic pulmonary hypertension ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Taijyu Satoh

Tohoku University Hospital, Sendai (Japan)

3 More presentations in this session

Presentation thumbnail
Loss of SRSF4 in cardiomyocytes induces hypertrophy, diastolic dysfunction and risk of sudden death
Mr J. Larrasa-Alonso (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Molecular mechanisms of arrhythmia upon TBX5 loss
Ms F. Rathjens (Goettingen, DE)
Abstract
Presentation thumbnail
Innate immune nod1/rip2 signaling is essential for cardiac hypertrophic response with a surprising critical interaction with mitochondrial danger activator
Doctor H. Lin (Ottawa, CA)
Abstract Slides Video

Access the full session

Session thumbnail
Young Investigator Awards Session Basic Science

The Event

Event poster

ESC Congress 2017

27 August 2017 15:10 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources